Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Inflammatory mediators and dual depression, Potential biomarkers in plasma of primary and substance-induced major depression in cocaine and alcohol use disorders

  • García Marchena, Nuria|||0000-0002-0575-3613
  • Barrera-Conde, Marta|||0000-0002-0106-0000
  • Mestre-Pintó, Joan-Ignasi|||0000-0003-0387-9375
  • Araos, Pedro|||0000-0001-5172-8796
  • Serrano, Antonia
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Papaseit, Esther|||0000-0003-2620-4274
  • Fonseca, Francina|||0000-0002-0779-6545
  • Ruiz, Juan Jesús
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Pavón, Francisco Javier
  • Torrens, Marta
Major depressive disorder (MDD) is the most prevalent comorbid mental disorder among people with substance use disorders. The MDD can be both primary and substance-induced and its accurate diagnosis represents a challenge for clinical practice and treatment response. Recent studies reported alterations in the circulating expression of inflammatory mediators in patients with psychiatric disorders, including those related to substance use. The aim of the study was to explore TNF-α, IL-1β, CXCL12, CCL2, CCL11 (eotaxin-1) and CX3CL1 (fractalkine) as potential biomarkers to identify comorbid MDD and to distinguish primary MDD from substance-induced MDD in patients with substance disorders. Patients diagnosed with cocaine (CUD, n = 64) or alcohol (AUD, n = 65) use disorders with/without MDD were recruited from outpatient treatment programs [CUD/non-MDD (n = 31 CUD/primary MDD (n = 18 CUD/cocaine-induced MDD (N = 15 AUD/non-MDD (n = 27 AUD/primary MDD (n = 16) and AUD/alcohol-induced MDD (n = 22)]. Sixty-two healthy subjects were also recruited as control group. Substance and mental disorders were assessed according to "Diagnostic and Statistical Manual of Mental Disorders, 4 edition, text revision" (DSM-IV-TR) and a blood sample was collected for determinations in the plasma. The cocaine group showed lower TNF-α (p<0.05) and CCL11 (p<0.05), and higher IL-1β (p<0.01) concentrations than the control group. In contrast, the alcohol group showed higher IL-1β (p<0.01) and lower CXCL12 (p<0.01) concentrations than the control group. Regarding MDD, we only observed alterations in the cocaine group. Thus, CUD/MDD patients showed lower IL-1β (p<0.05), CXCL12 (p<0.05) and CCL11 (p<0.05), and higher CXC3CL1 (p<0.05) concentrations than CUD/non-MDD patients. Moreover, while CUD/primary MDD patients showed higher CCL11 (p<0.01) concentrations than both CUD/non-MDD and CUD/cocaine-induced MDD patients, CUD/cocaine-induced MDD patients showed lower CXCL12 (p<0.05) concentrations than CUD/non-MDD patients. Finally, a logistic regression model in the cocaine group identified CXCL12, CCL11 and sex to distinguish primary MDD from cocaine-induced MDD providing a high discriminatory power. The present data suggest an association between changes in inflammatory mediators and the diagnosis of primary and substance-induced MDD, namely in CUD patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute Effects of 2C-E in Humans, An Observational Study

  • Papaseit, Esther|||0000-0003-2620-4274
  • Olesti, Eulàlia|||0000-0001-8677-9964
  • Pérez-Mañá, Clara|||0000-0001-6343-6918
  • Torrens, Marta
  • Grifell, Marc|||0000-0001-9815-5761
  • Ventura, Mireia|||0000-0003-1133-6872
  • Pozo, Oscar J.|||0000-0002-1735-9728
  • de Sousa Fernandes Perna, Elizabeth B.|||0000-0001-8580-1795
  • Ramaekers, Johannes G.|||0000-0003-4553-376X
  • Torre, Rafael de la|||0000-0002-6765-1866
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT), 2B (5-HT), and (5-HT) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic effects, but its pharmacology in humans, including pharmacological effects and pharmacokinetics, have not yet studied. To assess the acute effects of 2C-E on physiological and subjective effects and evaluate its pharmacokinetics, an observational study was carried-out. Ten recreational users of psychedelics self-administered a single oral dose of 2C-E (6.5, 8, 10, 15, or 25 mg). Blood pressure and heart rate were evaluated at baseline, 2, 4, and 6 h post-administration. Three rating scales were administered to evaluate subjective effects: a set of Visual Analog Scales (VAS), the 49-item short form version of the Addiction Research Centre Inventory (ARCI), and the Evaluation of the Subjective Effects of Substances with Abuse Potential (VESSPA-SSE) at baseline, 2, 4, and 6 h after self-administration. To assess 2C-E concentrations oral fluid (saliva) was collected during 6 h. 2C-E induced primarily alterations in perceptions, hallucinations, and euphoric-mood. Saliva maximal concentrations were achieved 2 h after self-administration. Administration of oral 2C-E at recreational doses produces a group of psychedelic-like effects such to 2C-B and other serotonin-acting drugs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Non-medical Use of Prescription Gabapentinoids (Gabapentin and Pregabalin) in Five European Countries

  • Fonseca, Francina|||0000-0002-0779-6545
  • Lenahan, William
  • Dart, Richard C.
  • Papaseit, Esther|||0000-0003-2620-4274
  • Dargan, Paul I.
  • Wood, David M.
  • Guareschi, Marilena
  • Maremmani, Icro
  • Auriacombe, Marc|||0000-0002-8938-8683
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Scherbaum, Norbert|||0000-0003-1759-6990
  • Torrens, Marta
Background: Non-medical use (NMU) of prescription GABA analogs (pregabalin and gabapentin) has been reported especially in opiate dependent persons. However, by now the prevalence of NMU of gabapentinoids in the general population has not been sufficiently evaluated. The aim of this research paper is to determine the prevalence of prescription GABA analog NMU and associated demographics in five European countries with special detail of Spain. Methods: The RADARS Survey of Non-Medical Use of Prescription Drugs Program (NMURx) is a harmonized series of contemporaneous cross-sectional surveys of adults conducted in multiple countries. NMURx collects data from the general population in each participating country about NMU of prescription drugs, illicit drugs, and associated demographics. NMU was defined as "using a medication without a doctor's prescription or for any reason other than what was recommended by their doctor." Responses from Spain (4Q2017, n =10,062) were analyzed in detail. Comparative data were available from France, Germany, Italy, and UK. Responses were collected using non-probability quota sampling and post-stratification population weighting was applied to reflect the national distributions of adults, based on age, gender, and census region. Rates of NMU and associated demographics were reported as rate of past 90-day NMU per 100,000 adult population with 95% confidence intervals. Results: Germany (1,197 per 100,000 adult population [95% CI: 1,004.3-1,379.1]) and United Kingdom (1,067 per 100,000 adult population [95% CI: 851.3-1,283.2]) presented the highest prevalence of gabapentinoids NMU. In Spain the prevalence of past 90 days GABA analog NMU was: 344.4, 95% (CI 204.8-484.0), with male predominance. Those who non-medically use GABA analogs had a higher prevalence of lifetime chronic pain, lifetime illicit drug use, and previous substance abuse treatment. In Spain, 20% of respondents who ever have used gabapentinoids, reported a lifetime NMU; the prevalence was higher for pregabalin 624 (6.2%) than for gabapentin 444 (4.4%). The main reasons for use were to self-treat pain and other medical conditions. Conclusions: The risk of NMU of gabapentinoids should not be neglected. Subjects with a history of chronic pain and lifetime substance use disorders had an increased risk of NMU of gabapentinoids.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder

  • Requena-Ocaña, Nerea|||0000-0003-3257-8459
  • Flores-López, María|||0000-0003-3489-1465
  • Papaseit, Esther|||0000-0003-2620-4274
  • García Marchena, Nuria|||0000-0002-0575-3613
  • Ruiz, Juan Jesús
  • Ortega-Pinazo, Jesús
  • Serrano, Antonia
  • Pavón-Morón, Francisco Javier|||0000-0002-5256-8904
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Suarez, Juan|||0000-0001-5254-9802
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Araos, Pedro|||0000-0001-5172-8796
(1) Background: Alcohol Use Disorder (AUD) is associated with functional disruption of several brain structures that may trigger cognitive dysfunction. One of the mechanisms of alcohol-associated cognitive impairment has been proposed to arise from its direct impact on the immune system, which culminates in the release of cytokines and chemokines which can eventually reach the brain. Alcohol can also disrupt the blood-brain barrier, facilitating the penetration of pro-inflammatory molecules throughout vascular endothelial growth factor A (VEGFA). Thus, alcohol-induced alterations in chemokines and VEGFA might contribute to the neuroinflammation and cognitive impairment associated with AUD. (2) Methods: The present cross-sectional study investigates whether patients with AUD (n = 86) present cognitive disability associated to alterations in plasma concentration of SDF-1, fractalkine, eotaxin, MCP-1, MIP-1α and VEGFA when compared to control subjects (n = 51). (3) Results: The analysis indicated that SDF-1 and MCP-1 concentrations were higher in AUD patients than in controls. Concentrations of VEGFA were higher in AUD patients with severe frontal deficits, and the score of frontal lobe functions was negatively correlated with VEGFA and fractalkine. Acute alcohol effects on VEGFA plasma levels in healthy volunteers demonstrated the induction of VEGFA release by heavy alcohol drinking. VEGFA was positively correlated with pro-inflammatory chemokines in AUD patients with frontal cognitive impairment. (4) Conclusions: we propose VEGFA/chemokine monitoring as biomarkers of potential cognitive impairment in AUD patients.